You are here

AstraZeneca heart drug fails in key stroke trial

DRUG23032016.jpg
[LONDON] AstraZeneca said on Wednesday its blood-thinning drug Brilinta failed to help stroke patients as hoped in a major clinical trial, dealing a blow to a product viewed as an important driver of future sales and profits.

[LONDON] AstraZeneca said on Wednesday its blood-thinning drug Brilinta failed to help stroke patients as hoped in a major clinical trial, dealing a blow to a product viewed as an important driver of future sales and profits.

The trial found that Brilinta was not significantly better than aspirin, the current standard of care, in preventing recurrent attacks in the 90 days after patients suffer a stroke.

REUTERS

sentifi.com

Market voices on:

grab

Receive $80 Grab vouchers valid for use on all Grab services except GrabHitch and GrabShuttle when you subscribe to BT All-Digital at only $0.99*/month.

Find out more at btsub.sg/promo

Powered by GET.comGetCom